Solange Peters to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Solange Peters has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
4.577
-
Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3).
Score: 0.456
-
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open. 2020 06; 5(Suppl 3).
Score: 0.433
-
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. Curr Treat Options Oncol. 2018 05 28; 19(7):37.
Score: 0.376
-
Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell. 2018 05 14; 33(5):791-793.
Score: 0.375
-
EML4-ALK Variant Affects ALK Resistance Mutations. J Clin Oncol. 2018 04 20; 36(12):1257-1259.
Score: 0.370
-
Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 11 16; 377(20):1986-1988.
Score: 0.363
-
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat Rev. 2018 Jan; 62:39-49.
Score: 0.361
-
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789.
Score: 0.352
-
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017 08 31; 377(9):829-838.
Score: 0.352
-
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol. 2017 04; 12(4):752-762.
Score: 0.341
-
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 11 21; 381(21):2020-2031.
Score: 0.103
-
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019 12; 14(12):2109-2119.
Score: 0.102
-
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2019 Aug; 46(9):1859-1868.
Score: 0.101
-
[The new management options for lung cancer in the immunotherapy era]. Rev Med Suisse. 2019 May 15; 15(651):1032-1037.
Score: 0.101
-
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol. 2019 01; 14(1):115-123.
Score: 0.096
-
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. J Thorac Oncol. 2018 12; 13(12):1851-1863.
Score: 0.096
-
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer. 2017 09; 111:143-149.
Score: 0.089
-
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017 05; 5(5):435-444.
Score: 0.087
-
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol. 2018 03; 13(3):413-425.
Score: 0.023